1.85 USD
-0.06 (-3.14%)
1.8356 USD
-0.01 (-0.78%)
LUNG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. LUNG has a bad profitability rating. Also its financial health evaluation is rather negative. LUNG shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
- In the past year LUNG has reported negative net income.
- In the past year LUNG has reported a negative cash flow from operations.
- LUNG had negative earnings in each of the past 5 years.
- In the past 5 years LUNG always reported negative operating cash flow.
1.2 Ratios
- LUNG has a worse Return On Assets (-41.04%) than 63.44% of its industry peers.
- With a Return On Equity value of -94.54%, LUNG is not doing good in the industry: 61.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.04% | ||
| ROE | -94.54% | ||
| ROIC | N/A |
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- LUNG has a Gross Margin of 73.30%. This is amongst the best in the industry. LUNG outperforms 82.80% of its industry peers.
- In the last couple of years the Gross Margin of LUNG has remained more or less at the same level.
- LUNG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
2. Health
2.1 Basic Checks
- LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for LUNG has been increased compared to 1 year ago.
- Compared to 5 years ago, LUNG has more shares outstanding
- LUNG has a worse debt/assets ratio than last year.
2.2 Solvency
- LUNG has an Altman-Z score of -4.51. This is a bad value and indicates that LUNG is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -4.51, LUNG is not doing good in the industry: 70.43% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.62 indicates that LUNG is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.62, LUNG is not doing good in the industry: 62.90% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.51 |
ROIC/WACCN/A
WACC10.63%
2.3 Liquidity
- LUNG has a Current Ratio of 4.86. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
- LUNG has a Current ratio of 4.86. This is in the better half of the industry: LUNG outperforms 78.49% of its industry peers.
- A Quick Ratio of 4.15 indicates that LUNG has no problem at all paying its short term obligations.
- LUNG's Quick ratio of 4.15 is fine compared to the rest of the industry. LUNG outperforms 76.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.86 | ||
| Quick Ratio | 4.15 |
3. Growth
3.1 Past
- LUNG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.40%.
- Looking at the last year, LUNG shows a quite strong growth in Revenue. The Revenue has grown by 15.59% in the last year.
- LUNG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.78% yearly.
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
Revenue 1Y (TTM)15.59%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%5.47%
3.2 Future
- The Earnings Per Share is expected to grow by 25.48% on average over the next years. This is a very strong growth
- Based on estimates for the next years, LUNG will show a very strong growth in Revenue. The Revenue will grow by 27.14% on average per year.
EPS Next Y-7.1%
EPS Next 2Y1.32%
EPS Next 3Y7.71%
EPS Next 5Y25.48%
Revenue Next Year8.99%
Revenue Next 2Y6.99%
Revenue Next 3Y11.66%
Revenue Next 5Y27.14%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for LUNG. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUNG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.32%
EPS Next 3Y7.71%
5. Dividend
5.1 Amount
- No dividends for LUNG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PULMONX CORP / LUNG FAQ
What is the fundamental rating for LUNG stock?
ChartMill assigns a fundamental rating of 3 / 10 to LUNG.
Can you provide the valuation status for PULMONX CORP?
ChartMill assigns a valuation rating of 0 / 10 to PULMONX CORP (LUNG). This can be considered as Overvalued.
Can you provide the profitability details for PULMONX CORP?
PULMONX CORP (LUNG) has a profitability rating of 1 / 10.
What is the financial health of PULMONX CORP (LUNG) stock?
The financial health rating of PULMONX CORP (LUNG) is 3 / 10.
Can you provide the expected EPS growth for LUNG stock?
The Earnings per Share (EPS) of PULMONX CORP (LUNG) is expected to decline by -7.1% in the next year.